Antibodies and kits for detecting carboxylated osteocalcin

High specific antibodies were screened out through hybridoma technology and kits were prepared, which solved the problem of poor specificity of existing antibodies, achieved high sensitivity carboxylated osteocalcin detection, and simplified the clinical diagnosis process.

CN118206647BActive Publication Date: 2024-11-19BEIJING SETH WADE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410294346.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-14
Publication Date
2024-11-19
Estimated Expiration
2044-03-14

AI Technical Summary

Technical Problem

The existing carboxylated osteocalcin antibodies have poor specificity and low sensitivity, and cannot effectively distinguish between carboxylated osteocalcin and uncarboxylated osteocalcin, making it difficult to determine the positive serum of carboxylated osteocalcin in clinical practice.

Method used

The hybridoma technology screened out antibodies that recognize carboxylated osteocalcin with strong specificity and high sensitivity, and prepared a kit to detect carboxylated osteocalcin, using antibodies or antigen-binding fragments, recombinant proteins, nucleic acid molecules, and expression Compositions such as vectors, recombinant cells and conjugates are subjected to high specificity detection.

Benefits of technology

High specificity and high sensitivity carboxylated osteocalcin detection is achieved, which can accurately distinguish between carboxylated and uncarboxylated osteocalcin, simplify the clinical diagnosis process, and improve the detection efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004741708580000121
    Figure BDA0004741708580000121
  • Figure BDA0004741708580000131
    Figure BDA0004741708580000131
  • Figure BDA0004741708580000161
    Figure BDA0004741708580000161
Patent Text Reader

Abstract

The present invention discloses an antibody or antigen-binding fragment. According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises a CDR selected from at least one of the following: a light chain variable region CDR sequence: SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5; a heavy chain variable region CDR sequence: SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8. The antibody or antigen-binding fragment according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biological detection, and specifically, the present invention relates to an antibody and a kit for detecting carboxylated osteocalcin. More specifically, the present invention relates to a recombinant protein, a nucleic acid molecule, an expression vector, a recombinant cell, a conjugate, a method for preparing an antibody or antigen fragment that recognizes the carboxylation site of osteocalcin, a composition, a method for detecting carboxylated osteocalcin, and its use. Background Art

[0002] Osteocalcin (OC) is a non-collagenous bone matrix protein specifically synthesized and secreted by non-proliferating osteoblasts in bones. The precursor protein consists of a 23-amino acid signal peptide, a 28-amino acid propeptide, and a 49-amino acid mature protein. In the post-expression modification stage, the signal peptide is hydrolyzed, and the propeptide recognition site binds to the carboxylase to carboxylate the Glu at positions 17, 21, and 24 to Gla, also known as bone γ-carboxyglutamate protein.

[0003] Carboxylated osteocalcin has the function of promoting bone mineralization. It can tightly bind to hydroxyapatite and form a complex with collagen through osteopontin. It is an important component of bone mineralization matrix. Carboxylated osteocalcin is not limited to being a traditional physiological indicator reflecting bone transformation. There are estrogen receptors on osteoblasts. After menopause, the estrogen level of women decreases, and the degree of vascular arteriosclerosis also increases accordingly. After the decrease of estrogen, the activity of osteoclasts increases, so that osteoclasts absorb bone and release more osteocalcin. The carboxylated osteocalcin will in turn inhibit the development of atherosclerosis.

[0004] Usually carboxylated osteocalcin decreases with age. Once carboxylated osteocalcin is low, it is likely that the body's calcium metabolism is abnormal. The physiological factors that cause low carboxylated osteocalcin are mainly due to the lack of calcium ions. Among the pathological factors, liver disease, rheumatoid arthritis, diabetes, rheumatoid arthritis, hypoparathyroidism and excessive use of hormone drugs may cause a decrease in carboxylated osteocalcin, and the decrease in serum carboxylated osteocalcin is significantly correlated with the severity of peripheral arterial and coronary artery sclerosis.

[0005] When the cells that synthesize bones in the human body are relatively active, the content of carboxylated osteocalcin in human serum increases. If carboxylated osteocalcin appears significantly higher, it may be caused by diseases such as bone trauma, osteomalacia or rheumatoid arthritis. In addition, diseases such as primary hyperthyroidism, menopausal syndrome, premature ovarian failure, and osteoporosis may all lead to elevated carboxylated osteocalcin. When bone tumors or bone metastases of malignant tumors occur, such as osteosarcoma and giant cell tumors of bone, abnormal increases in carboxylated osteocalcin may also occur. Since osteocalcin is a non-collagen glycoprotein, higher levels of osteocalcin have certain adverse effects on the body, and damage such as osteoporosis, bone trauma, osteomalacia, and bone trauma may occur. In severe cases, bone cancer may occur. However, existing carboxylated osteocalcin antibodies have poor specificity and low sensitivity, and cannot effectively distinguish between carboxylated osteocalcin antibodies and non-carboxylated osteocalcin.

[0006] Currently, there is an urgent need to develop an antibody with strong specificity and high sensitivity to recognize carboxylated osteocalcin for the detection of carboxylated osteocalcin. Summary of the invention

[0007] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0008] The inventors found that osteocalcin exists in two forms, namely carboxylated osteocalcin and uncarboxylated osteocalcin. Existing carboxylated osteocalcin antibodies are difficult to distinguish between the two forms of osteocalcin, which makes it difficult to determine the positive serum of clinical carboxylated osteocalcin. In order to overcome this problem, the inventors used hybridoma technology to screen out an antibody that recognizes carboxylated osteocalcin with strong specificity and high sensitivity, and used it to prepare a kit to detect carboxylated osteocalcin.

[0009] In the first aspect of the present invention, the present invention provides an antibody or antigen-binding fragment. According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises a CDR selected from at least one of the following: a light chain variable region CDR sequence: SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5; a heavy chain variable region CDR sequence: SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8. The antibody or antigen-binding fragment according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.

[0010] In a second aspect of the present invention, the present invention provides a recombinant protein. According to an embodiment of the present invention, the recombinant protein includes the antibody or antigen-binding fragment described in the first aspect of the present invention. The recombinant protein according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.

[0011] In the third aspect of the present invention, the present invention provides a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes the antibody or antigen-binding fragment described in the first aspect of the present invention or the recombinant protein described in the second aspect of the present invention. According to an embodiment of the present invention, the antibody or antigen-binding fragment thereof encoded by the nucleic acid molecule can be used to specifically detect carboxylated osteocalcin.

[0012] In a fourth aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the nucleic acid molecule described in the third aspect of the present invention. According to an embodiment of the present invention, the expression vector can efficiently express the antibody or antigen-binding fragment thereof in a suitable host cell for specific detection of carboxylated osteocalcin or preparation of a drug related to a carboxylated osteocalcin disease.

[0013] In a fifth aspect of the present invention, a recombinant cell is provided. According to an embodiment of the present invention, the recombinant cell comprises: carrying the nucleic acid molecule described in the third aspect of the present invention, or the expression vector described in the fourth aspect of the present invention; or expressing the antibody or antigen-binding fragment described in the first aspect of the present invention, or the recombinant protein described in the second aspect of the present invention. According to an embodiment of the present invention, the recombinant cell can efficiently express the above-mentioned antibody or antigen-binding fragment thereof under appropriate conditions, and the antibody or antigen-binding fragment thereof can specifically bind to carboxylated osteocalcin.

[0014] In a sixth aspect of the present invention, the present invention provides a conjugate. According to an embodiment of the present invention, the conjugate comprises: the antibody or antigen-binding fragment described in the first aspect of the present invention or the recombinant protein described in the second aspect of the present invention; and a coupling portion, wherein the coupling portion is connected to the antibody or antigen-binding fragment, or the recombinant protein. According to an embodiment of the present invention, the conjugate can bind to carboxylated osteocalcin with high specificity.

[0015] In a seventh aspect of the present invention, the present invention provides a method for preparing an antibody or antigen fragment that recognizes the carboxylation site of osteocalcin. According to an embodiment of the present invention, the method comprises: culturing the recombinant cell described in the fifth aspect of the present invention. The method according to an embodiment of the present invention can prepare a large amount of antibodies or antigen fragments that bind to carboxylated osteocalcin with high specificity.

[0016] In the eighth aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition comprises: the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, and the conjugate described in the sixth aspect of the present invention. The composition according to an embodiment of the present invention, comprising the aforementioned antibody or antigen-binding fragment thereof, such as a composition of the aforementioned antibody or antigen-binding fragment thereof and a buffer, a food composition, a pharmaceutical composition, etc., can also bind carboxylated osteocalcin with high specificity.

[0017] In the ninth aspect of the present invention, the present invention proposes the use of the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention in preparing a kit. According to an embodiment of the present invention, the kit is used to detect carboxylated osteocalcin.

[0018] In the tenth aspect of the present invention, the present invention proposes a kit. According to an embodiment of the present invention, the kit comprises: at least one of the antibody or antigen binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, and the composition described in the eighth aspect of the present invention. According to an embodiment of the present invention, the aforementioned antibody or its antigen binding fragment can bind carboxylated osteocalcin with high specificity. Therefore, the kit containing the aforementioned antibody or its antigen binding fragment can be used for high specificity and high sensitivity detection of carboxylated osteocalcin. In some scientific studies, the kit of the embodiment of the present invention can be used for qualitative or quantitative detection of carboxylated osteocalcin protein in biological samples, and can also be used to judge the status of an individual, such as after obtaining the carboxylated osteocalcin level of the individual, judging whether the carboxylated osteocalcin level is higher or lower than the normal level.

[0019] In the eleventh aspect of the present invention, the present invention proposes use of the kit described in the tenth aspect of the present invention in preparing a carboxylated osteocalcin detection product.

[0020] In the twelfth aspect of the present invention, the present invention proposes a method for detecting carboxylated osteocalcin. According to an embodiment of the present invention, the method comprises: using the antibody or antigen binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, or the kit described in the tenth aspect of the present invention to detect and process the sample to be tested. The method according to the embodiment of the present invention can be used for high-sensitivity detection of carboxylated osteocalcin, and has strong specificity and simple operation. In practical clinical applications, large quantities of samples can be quickly and high-throughput detected with the help of a chemiluminometer.

[0021] The thirteenth aspect of the present invention is the use of the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, and the composition described in the eighth aspect of the present invention in the preparation of a drug.

[0022] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0024] Figure 1 is a schematic diagram of the subtype detection results of W027 antibody in Example 6;

[0025] Figure 2 It is a schematic diagram of the process of the chemiluminescent immunoassay method for separating carboxylated osteocalcin magnetic particles in Example 9. DETAILED DESCRIPTION

[0026] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0027] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0028] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.

[0029] In the present invention, the terms "comprise" or "include" are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.

[0030] In the present invention, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or situation can but does not necessarily occur, and the description includes cases where the event or situation occurs and cases where it does not occur.

[0031] The endpoints and any values ​​of the ranges disclosed in the present invention are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be considered as specifically disclosed in this article.

[0032] In the present invention, the term "expression vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and transfers the inserted nucleic acid molecule into and / or between host cells. The expression vector may include a vector that is mainly used to insert DNA or RNA into a cell, a vector that is mainly used to replicate DNA or RNA, and a vector that is mainly used for the expression of transcription and / or translation of DNA or RNA. The expression vector also includes vectors with multiple of the above functions. The expression vector may be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the expression vector can produce a desired expression product by culturing a suitable host cell containing the expression vector.

[0033] In the present invention, the term "recombinant cell" generally refers to the use of genetic engineering technology or cell fusion technology to modify or reorganize the genetic material of the host cell to obtain a cell with a unique trait of stable inheritance. Among them, the term "host cell" refers to a prokaryotic cell or eukaryotic cell that can be introduced into a recombinant expression vector. The terms "transformed" or "transfected" used in the present invention refer to the introduction of nucleic acids (such as vectors) into cells by various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of the present invention, and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used in the present invention include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid) and CoS cells.

[0034] In the present invention, the abbreviations for amino acid residues are the standard three-letter and / or one-letter codes used in the art to refer to one of the 20 commonly used L-amino acids, and have the following meanings: A: Ala (alanine); R: Arg (arginine); N: Asn (asparagine); D: Asp (aspartic acid); C: Cys (cysteine); Q: Gln (glutamine); E: Glu (glutamate); G: Gly (glycine); H: His (histidine); I: Ile (isoleucine); L: Leu (leucine); K: Lys (lysine); M: Met (methionine); F: pHe (phenylalanine); P: Pro (proline); S: Ser (serine); T: Thr (threonine); W: Trp (tryptophan); Y: Tyr (tyrosine); V: Val (valine).

[0035] In the present invention, when the term "identity" is used to describe an amino acid sequence or a nucleic acid sequence relative to a reference sequence, the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., ed. (1995), Current Protocols in MolecμLar Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 48:443); the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:24 ... .70:173-187 (1997); and BLASTP, BLASTN, and BLASTX algorithms (see Altsch μL et al. (1990) J. Mol. Biol. 215:403-410). Computer programs that utilize these algorithms are also available, and include, but are not limited to: ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altsch μL et al., Meth. Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altsch μL et al., supra, FASTA, and TFASTA, available in the Genetics Computing Group (GCG) package, Version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0036] In the present invention, without substantially affecting the activity of the antibody (retaining at least 95% of the activity), those skilled in the art may replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present application to obtain a variant of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The variant sequence described in the present application may have at least 80% identity (or homology) with the reference sequence, which means at least 80% with each reference sequence, which may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity. The sequence consistency described in the present application can be measured using sequence analysis software. For example, the computer program BLAST, especially BLASTP or TBLASTN, with default parameters is used. The amino acid sequences described in the present invention are all shown in the manner of N-terminus to C-terminus.

[0037] The present invention provides an antibody or antigen-binding fragment, a recombinant protein, a nucleic acid molecule, an expression vector, a recombinant cell, a conjugate, a method for preparing an antibody or antigen-binding fragment that recognizes the carboxylation site of osteocalcin, a composition, use in preparing a kit, a kit, use in preparing a carboxylated osteocalcin detection product, a method for detecting carboxylated osteocalcin, and use in preparing a drug, which will be described in detail below.

[0038] Antibodies or antigen-binding fragments

[0039] In the first aspect of the present invention, the present invention provides an antibody or antigen-binding fragment. According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises a CDR selected from at least one of the following: a light chain variable region CDR sequence: SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or an amino acid sequence of a conservative modification thereof; a heavy chain variable region CDR sequence: SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 or an amino acid sequence of a conservative modification thereof. The antibody or antigen-binding fragment according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.

[0040] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises a CDR selected from at least one of the following: light chain variable region CDR sequence: SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5; heavy chain variable region CDR sequence: SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8. The antibody or antigen-binding fragment according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.

[0041] In the present invention, the term "antibody" is used in the broadest sense, which can include full-length monoclonal antibodies, multispecific antibodies, and chimeric antibodies, and the specific structure is not limited as long as they show the desired biological activity. It usually includes a light chain with a lighter molecular weight and a heavy chain with a heavier molecular weight, and the heavy chain (H chain) and the light chain (L chain) are connected by a disulfide bond to form an antibody molecule. Among them, the amino acid sequence of the amino terminal (N terminal) of the peptide chain varies greatly, which is called the variable region (V region); the carboxyl terminal (C terminal) is relatively stable and varies little, which is called the constant region (C region). The V regions of the L chain and the H chain are respectively called VL and VH. As used herein, the term "complementarity determining region", "CDR" or "CDRs" refers to the highly variable region of the heavy chain and light chain of an immunoglobulin, and refers to a region containing one or more or even all of the main amino acid residues that play a role in the binding affinity of the antibody or its functional fragment to the antigen or epitope it recognizes. In a specific embodiment of the present disclosure, CDRs refers to the highly variable region of the heavy chain and light chain of the antibody.

[0042] In the present invention, the term "antigen-binding fragment" is a fragment comprising part or all of an antibody, which lacks at least some of the amino acids present in the full-length chain but is still capable of specifically binding to an antigen, for example, the fragment may comprise part or all of an antibody CDR. Such fragments are biologically active because they bind to an antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments are selected from Fab, Fv, scFv or single-domain antibodies. Such fragments can be produced by recombinant nucleic acid technology, or can be produced by enzymatic cleavage or chemical cleavage of antigen-binding molecules (including intact antibodies).

[0043] In the present invention, "conservatively modified forms of amino acid sequences" refer to amino acid modifications that do not significantly affect or alter the binding properties of antibodies comprising the amino acid sequence, including amino acid substitutions, additions and deletions. Modifications can be introduced into the antibodies of the present invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been identified in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR region of an antibody of the invention may be replaced by other amino acid residues from the same side chain family, and the retained function of the altered antibody may be tested using the functional assays described herein. Preferably, conservative modifications are no more than 1 or 2 in number.

[0044] In the present invention, those skilled in the art will know that the "SEQ ID NO" sequence shown in the present invention and the amino acid sequence with at least 80% homology thereto and the amino acid sequence with conservative modifications thereto should all be regarded as equivalent sequences. For example, the SEQ ID NO: 3 sequence or the amino acid sequence with at least 80% homology thereto or the amino acid sequence with conservative modifications thereto should all be regarded as equivalent sequences in the art.

[0045] According to an embodiment of the present invention, the above-mentioned antibody or antigen-binding fragment may further include at least one of the following additional technical features:

[0046] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: light chain variable region CDR1, CDR2, and CDR3 sequences as shown in SEQ ID NO: 3 or an amino acid sequence having at least 80% homology thereto, SEQ ID NO: 4 or an amino acid sequence having at least 80% homology thereto, and SEQ ID NO: 5 or an amino acid sequence having at least 80% homology thereto.

[0047] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: heavy chain variable region CDR1, CDR2, and CDR3 sequences as shown in SEQ ID NO: 6 or an amino acid sequence having at least 80% homology thereto, SEQ ID NO: 7 or an amino acid sequence having at least 80% homology thereto, and SEQ ID NO: 8 or an amino acid sequence having at least 80% homology thereto.

[0048] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: light chain variable region CDR1, CDR2, and CDR3 sequences as shown in the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively.

[0049] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: heavy chain variable region CDR1, CDR2, and CDR3 sequences as shown in the amino acid sequences of SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, respectively.

[0050] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: a light chain variable region as shown in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% homology thereto, and a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% homology thereto.

[0051] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: a light chain variable region as shown in the amino acid sequence of SEQ ID NO:1, and a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO:2.

[0052] According to an embodiment of the present invention, the antibody or antigen-binding fragment further comprises at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from a mammalian antibody.

[0053] According to an embodiment of the present invention, the heavy chain constant region and the light chain constant region are derived from at least one of mouse antibody, human antibody, primate antibody, bovine antibody, horse antibody, dairy cow antibody, porcine antibody, sheep antibody, goat antibody, dog antibody, cat antibody, rabbit antibody, camel antibody, donkey antibody, deer antibody, mink antibody or their mutants.

[0054] According to an embodiment of the present invention, the heavy chain constant region includes a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; or the light chain constant region includes a light chain constant region selected from κ type or λ type.

[0055] According to an embodiment of the present invention, the heavy chain constant region and the light chain constant region are both derived from murine antibodies or mutants thereof.

[0056] According to an embodiment of the present invention, the N-terminus of the heavy chain constant region is connected to the C-terminus of the heavy chain variable region; and / or

[0057] The N-terminus of the light chain constant region is connected to the C-terminus of the light chain variable region.

[0058] According to an embodiment of the present invention, the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO:11 or an amino acid sequence having at least 80% homology thereto; and / or the light chain constant region comprises the amino acid sequence shown in SEQ ID NO:12 or an amino acid sequence having at least 80% homology thereto.

[0059] According to an embodiment of the present invention, the heavy chain constant region includes the amino acid sequence shown in SEQ ID NO:11; and / or the light chain constant region includes the amino acid sequence shown in SEQ ID NO:12.

[0060] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: a heavy chain having an amino acid sequence as shown in SEQ ID NO: 13 or an amino acid sequence having at least 80% homology thereto; and / or a light chain having an amino acid sequence as shown in SEQ ID NO: 14 or an amino acid sequence having at least 80% homology thereto.

[0061] According to an embodiment of the present invention, the antibody or antigen-binding fragment comprises: a heavy chain having an amino acid sequence as shown in SEQ ID NO:13; and / or a light chain having an amino acid sequence as shown in SEQ ID NO:14.

[0062] According to an embodiment of the present invention, the antibody includes at least one selected from a polyclonal antibody, a full-length monoclonal antibody, a Fab antibody, a Fab' antibody, a F(ab')2 antibody, a Fv antibody, a single-chain antibody, a single-domain antibody and a minimum recognition unit; or the antigen-binding fragment includes at least one selected from a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a F(ab)2 fragment, a Fv fragment, a scFv fragment, a scFv-Fc fusion protein, a scFv-Fv fusion protein and a minimum recognition unit.

[0063] In the present invention, the terms "full-length antibody", "full-length monoclonal antibody" or "full-length monoclonal antibody" are composed of at least two identical light chains and at least two identical heavy chains connected by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD) or immunoglobulin E (IgE).

[0064] In the present invention, the terms "polyantibody" and "multispecific antibody" are synonymous, and both refer to antibodies that can recognize multiple antigenic epitopes, such as antibodies that can recognize two antigenic epitopes (bispecific antibodies, referred to as bispecific antibodies), antibodies that recognize three antigenic epitopes, or antibodies that recognize four antigenic epitopes. They are understood in a broad sense, and the specific structure is not limited, as long as they can recognize multiple antigenic epitopes. In the present invention, at least one of the multiple antigenic epitopes is derived from carboxylated osteocalcin.

[0065] In the present invention, the terms "single domain antibody", "nanoantibody" and "VHH antibody" are used interchangeably, which were originally described as antigen-binding immunoglobulin (variable) domains of "heavy chain antibodies" (i.e., "antibodies lacking light chains") (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)), comprising a heavy chain variable region (VH) and conventional CH2 and CH3 regions, which specifically bind to antigen proteins (e.g., carboxylated osteocalcin) through the heavy chain variable region.

[0066] In the present invention, the term "Fab antibody" or "Fab fragment" generally refers to an antibody or fragment containing only Fab molecules, which is composed of VH and CH1 of the heavy chain and a complete light chain, and the light chain and the heavy chain are connected by a disulfide bond.

[0067] In the present invention, the term "F(ab')2 antibody" or "F(ab')2 fragment" has two antigen-binding F(ab') portions linked together by a disulfide bond.

[0068] In the present invention, the term "Fv antibody" or "Fv fragment" generally refers to an antibody or fragment composed only of a light chain variable region (VL) and a heavy chain variable region (VH) connected by non-covalent bonds, and is the smallest functional fragment of an antibody that retains a complete antigen binding site.

[0069] In the present invention, the terms "single-chain antibody" and "scFv fragment" refer to antibodies or fragments formed by connecting the heavy chain variable region and the light chain variable region of an antibody via a short peptide.

[0070] In the present invention, the terms "minimum recognition unit" and "MRU" both refer to an antibody or fragment consisting of only one CDR, and its molecular weight is very small and only accounts for about 1% of the complete antibody.

[0071] Recombinant protein

[0072] In a second aspect of the present invention, the present invention provides a recombinant protein. According to an embodiment of the present invention, the recombinant protein includes the antibody or antigen-binding fragment described in the first aspect of the present invention. The recombinant protein according to an embodiment of the present invention can be used to specifically detect carboxylated osteocalcin.

[0073] According to an embodiment of the present invention, the recombinant protein further includes at least one selected from a biologically active protein or a fragment thereof, a biologically active polypeptide or a fragment thereof.

[0074] According to an embodiment of the present invention, the biologically active protein or fragment thereof includes at least one selected from protein tags, protein toxins or fragments thereof, tumor necrosis factor or fragments thereof, interferon or fragments thereof, biological response regulators or fragments thereof and Fc fragments.

[0075] In the present invention, "protein tag" generally refers to a polypeptide or protein fused with a target protein (antibody or antigen binding fragment), which can be used for the expression, detection, disappearance or purification of the target protein, etc., including but not limited to His tag (also known as His-Tag, sequence HHHHHH), Flag tag (also known as Flag-Tag, sequence DYKDDDDK), GST tag (also known as GST-Tag, glutathione sulfhydryl transferase tag), MBP tag (also known as MBP-Tag, maltose binding protein tag), SUMO tag and C-Myc tag, etc.

[0076] In the present invention, "toxin" generally refers to a substance toxic to the host, including protein toxins and non-protein toxins. Among them, protein toxins include but are not limited to abrin, ricin A, Pseudomonas exotoxin and diphtheria toxin. In the present invention, the protein toxin is preferably a protein toxin with enzymatic activity.

[0077] In the present invention, "tumor necrosis factor" generally refers to a substance that can cause hemorrhagic necrosis in various tumors, including but not limited to TNF-α and TNF-β.

[0078] In the present invention, "interferon" generally refers to a glycoprotein that has the ability to directly kill or inhibit viruses, including but not limited to IFN-α, INF-β and IFN-γ.

[0079] In the present invention, "biological response modifiers" generally refer to a class of protein substances that directly or indirectly enhance the body's anti-tumor effect through the immune system, including but not limited to lymphokines, IL-2, IL-6, IL-10 and GM-CSF.

[0080] In the present invention, "Fc fragment" generally refers to the Fc region from IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM, including CH2, CH3 region and optionally hinge region. Preferably, IgG, IgA1, IgA2, IgD, IgE or IgM is derived from mouse, human, primate or alpaca.

[0081] Nucleic acid molecules, expression vectors, recombinant cells

[0082] In the third aspect of the present invention, the present invention provides a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes the antibody or antigen-binding fragment described in the first aspect of the present invention or the recombinant protein described in the second aspect of the present invention. According to an embodiment of the present invention, the antibody or antigen-binding fragment thereof encoded by the nucleic acid molecule can be used to specifically detect carboxylated osteocalcin.

[0083] According to an embodiment of the present invention, the nucleic acid molecule comprises: a nucleic acid sequence encoding a light chain variable region as shown in SEQ ID NO:9; or a nucleic acid sequence encoding a heavy chain variable region as shown in SEQ ID NO:10.

[0084] According to an embodiment of the present invention, the nucleic acid molecule comprises: a nucleic acid sequence encoding a light chain variable region as shown in SEQ ID NO:9 or having at least 80% homology thereto; or a nucleic acid sequence encoding a heavy chain variable region as shown in SEQ ID NO:10 or having at least 80% homology thereto.

[0085] According to an embodiment of the present invention, the nucleic acid molecule is DNA.

[0086] It should be noted that, for the nucleic acid molecules mentioned in the specification and claims of this application, those skilled in the art should understand that they actually include any one or both of the complementary double strands. For convenience, in this specification and claims, although only one strand is given in most cases, the other strand complementary thereto is actually disclosed. In addition, the nucleic acid sequence in this application includes DNA form or RNA form, and disclosing one of them means that the other is also disclosed.

[0087] The nucleotide sequences of the nucleic acid molecules mentioned in this application can be obtained by techniques known to those skilled in the art, and can also be species optimized to make them easier to express in mammalian cells.

[0088] In a fourth aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the nucleic acid molecule described in the third aspect of the present invention. According to an embodiment of the present invention, the expression vector can efficiently express the antibody or antigen-binding fragment thereof in a suitable host cell for specific detection of carboxylated osteocalcin or preparation of a drug related to a carboxylated osteocalcin disease.

[0089] It should be noted that when the above-mentioned nucleic acid molecules are connected to the vector, the nucleic acid molecules can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecules. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecules can be operably connected to the control elements. Herein, "operably connected" means that the exogenous gene is connected to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their expected functions of regulating the transcription and translation of the exogenous gene. Commonly used vectors can be, for example, plasmids, bacteriophages, etc., such as pcDNA plasmids.

[0090] In a fifth aspect of the present invention, a recombinant cell is provided. According to an embodiment of the present invention, the recombinant cell comprises: carrying the nucleic acid molecule described in the third aspect of the present invention, or the expression vector described in the fourth aspect of the present invention; or expressing the antibody or antigen-binding fragment described in the first aspect of the present invention, or the recombinant protein described in the second aspect of the present invention. According to an embodiment of the present invention, the recombinant cell can efficiently express the above-mentioned antibody or antigen-binding fragment thereof under appropriate conditions, and the antibody or antigen-binding fragment thereof can specifically bind to carboxylated osteocalcin.

[0091] It should be noted that the recombinant cells of the present application are not particularly limited and can be prokaryotic cells, eukaryotic cells or bacteriophages. Prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. Eukaryotic cells can be fungi including Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces, Trichoderma, insect cells such as Sphaerotheca serrata, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc. In certain embodiments, the recombinant cells of the present application are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0092] It should be noted that the "suitable conditions" in the specification of this application refer to conditions suitable for the expression of the antibody or its antigen-binding fragment of the present application. It is easy for those skilled in the art to understand that conditions suitable for the expression of recombinant antibodies include but are not limited to suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of recombinant antibodies according to the specific environment of the laboratory.

[0093] Conjugate

[0094] In a sixth aspect of the present invention, the present invention provides a conjugate. According to an embodiment of the present invention, the conjugate comprises: the antibody or antigen-binding fragment described in the first aspect of the present invention or the recombinant protein described in the second aspect of the present invention; and a coupling portion, wherein the coupling portion is connected to the antibody or antigen-binding fragment, or the recombinant protein. According to an embodiment of the present invention, the conjugate can bind to carboxylated osteocalcin with high specificity.

[0095] According to an embodiment of the present invention, the coupling part includes at least one selected from a carrier, a drug, a toxin, a cytokine, a protein tag, a modifier and a chemotherapeutic agent.

[0096] In the present invention, the carrier can be a substance that can be suspended or dispersed in a liquid phase (for example, solid phase carriers such as particles and magnetic beads), or a solid phase that can contain or carry a liquid phase (for example, a support such as a plate, a membrane, a test tube, and a container such as a well plate, a microfluidic channel, a glass capillary, a nanocolumn, a monolithic column, etc.); it can also be a labeling carrier for labeling antibodies or antigen-binding fragments, recombinant proteins or multispecific antibodies, such as enzymes (for example, peroxidase, alkaline phosphatase, luciferin, β-galactosidase, etc.). glycosidase), affinity substances (for example, one of streptavidin and biotin, one of the positive and antisense nucleic acids complementary to each other), fluorescent substances (for example, fluorescein, fluorescein isothiocyanate, rhodamine, green fluorescent protein, red fluorescent protein), luminescent substances (for example, luciferin, aequorin, acridinium ester, tris (2,2' bipyridine) ruthenium, luminol), radioactive isotopes (for example, 3H, 14C, 32P, 35S, 125I) and gold colloid, etc.

[0097] According to an embodiment of the present invention, the drug is a small molecule drug that can be combined with an antibody or an antigen-binding fragment or a recombinant protein.

[0098] According to an embodiment of the present invention, the protein tag includes but is not limited to a His tag, a Flag tag, a GST tag, an MBP tag, a SUMO tag, a C-Myc tag, and the like.

[0099] According to the embodiments of the present invention, the modifier should be understood in a broad sense, and may refer to a substance used to modify a protein. For example, it may be polyethylene glycol or a derivative thereof.

[0100] According to an embodiment of the present invention, the chemotherapeutic agents include but are not limited to albumin paclitaxel, cyclophosphamide, ifosfamide, phenylalanine mustard, methotrexate, fluorouracil, actinomycin D and vincristine.

[0101] It should be noted that the method for binding the coupling part and the antibody or antigen-binding fragment or recombinant protein can use methods known in the art. For example, physical adsorption, covalent binding, methods using affinity substances (e.g., biotin, streptavidin) and ion binding methods can be cited.

[0102] Method for preparing antibodies or antigen fragments that recognize osteocalcin carboxylation sites

[0103] In a seventh aspect of the present invention, the present invention provides a method for preparing an antibody or antigen fragment that recognizes the carboxylation site of osteocalcin. According to an embodiment of the present invention, the method comprises: culturing the recombinant cell described in the fifth aspect of the present invention. The method according to an embodiment of the present invention can prepare a large amount of antibodies or antigen fragments that bind to carboxylated osteocalcin with high specificity.

[0104] Composition

[0105] In the eighth aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition comprises: the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, and the conjugate described in the sixth aspect of the present invention. The composition according to an embodiment of the present invention, comprising the aforementioned antibody or antigen-binding fragment thereof, such as a food composition, a pharmaceutical composition, etc., can also bind to carboxylated osteocalcin with high specificity.

[0106] It should be noted that the composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present invention. For example, the components contained in the composition can be administered to the subject as a whole, or separately. When the components contained in the composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.

[0107] In addition, it needs to be further explained that the composition includes a pharmaceutical composition and a non-pharmaceutical composition, and the non-pharmaceutical composition includes a composition of the aforementioned antibody or antigen-binding fragment thereof and a buffer solution.

[0108] It needs to be further explained that the pharmaceutical composition of the embodiment of the present invention further includes pharmaceutically acceptable excipients.

[0109] The administration of the pharmaceutical composition of the present invention can be carried out by any acceptable mode of administration. The pharmaceutical composition of the present invention can be formulated into a solid, semisolid, liquid or gaseous preparation, such as an injection, a lyophilized powder, and the current methods for preparing these dosage forms are known or obvious to those skilled in the art. Typical routes of administration of such pharmaceutical compositions include, but are not limited to, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal and intranasal routes. The term parenteral as used herein includes subcutaneous injection, intravenous, intramuscular, intradermal, intrasternal injection or infusion techniques. The pharmaceutical composition of the present invention is formulated so as to allow the biologically active ingredients contained therein to be bioavailable after the composition is administered to a patient.

[0110] Use in the preparation of kits

[0111] In the ninth aspect of the present invention, the present invention proposes the use of the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention in preparing a kit. According to an embodiment of the present invention, the kit is used to detect carboxylated osteocalcin.

[0112] Reagent test kit

[0113] In the tenth aspect of the present invention, the present invention proposes a kit. According to an embodiment of the present invention, the kit comprises: at least one of the antibody or antigen binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, and the composition described in the eighth aspect of the present invention. According to an embodiment of the present invention, the aforementioned antibody or its antigen binding fragment can bind carboxylated osteocalcin with high specificity. Therefore, the kit containing the aforementioned antibody or its antigen binding fragment can be used for high specificity and high sensitivity detection of carboxylated osteocalcin. In some scientific studies, the kit of the embodiment of the present invention can be used for qualitative or quantitative detection of carboxylated osteocalcin protein in biological samples, and can also be used to judge the status of an individual, such as after obtaining the carboxylated osteocalcin level of the individual, judging whether the carboxylated osteocalcin level is higher or lower than the normal level.

[0114] According to an embodiment of the present invention, the kit comprises the antibody or antigen-binding fragment according to the first aspect of the present invention, magnetic particles, a second osteocalcin antibody, and a luminescent substrate; wherein the magnetic particles are coupled to the antibody or antigen-binding fragment;

[0115] The second osteocalcin antibody is modified with a marker; the marker is used to catalyze the luminescent substrate to emit light. It should be noted that in practical applications, the marker is compatible with the luminescent substrate.

[0116] According to an embodiment of the present invention, the particle size of the magnetic particles is no greater than 10 μm.

[0117] According to an embodiment of the present invention, the particle size of the magnetic particles is 0.5-10 μm.

[0118] According to an embodiment of the present invention, the particle size of the magnetic microspheres is selected from 0.5-10 μm, preferably 3-8 μm, and optionally 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, or 10 μm.

[0119] According to an embodiment of the present invention, the marker includes at least one of a biological enzyme, a fluorescein, and a chemiluminescent marker.

[0120] According to an embodiment of the present invention, the biological enzyme includes at least one of horseradish peroxidase and alkaline phosphatase. According to an embodiment of the present invention, the biological enzyme is compatible with the biomarker substrate, that is, the biological enzyme has the activity of catalyzing the luminescence of the biomarker substrate.

[0121] According to an embodiment of the present invention, the fluorescein is selected from at least one of fluorescein isothiocyanate, tetraethylrhodamine and tetramethylrhodamine isothiocyanate.

[0122] According to an embodiment of the present invention, the chemiluminescent marker is selected from at least one of acridinium ester, terpyridine ruthenium, isoluminol or a derivative thereof.

[0123] According to an embodiment of the present invention, the second osteocalcin antibody specifically recognizes the conserved region of osteocalcin.

[0124] According to an embodiment of the present invention, the luminescent substrate is selected from at least one of o-phenylenediamine, luminol and acridinium ester.

[0125] According to an embodiment of the present invention, the luminescent substrate is provided in liquid form.

[0126] According to an embodiment of the present invention, the luminescent substrate liquid further includes a buffer solution.

[0127] According to an embodiment of the present invention, the buffer solution includes at least one selected from phosphate buffer, carbonate buffer, tris buffer, and citrate buffer. The concentration of the buffer is selected from 10 to 100 mM, optionally 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM or 100 mM; the pH of the buffer is selected from 6.0 to 9.0, optionally 6.0, 7.0, 8.0 or 9.0.

[0128] According to an embodiment of the present invention, the kit further comprises a calibrator of carboxylated osteocalcin protein and / or a quality control product of carboxylated osteocalcin protein.

[0129] According to some optional embodiments of the present invention, the calibrator comprises carboxylated osteocalcin at different concentration gradients.

[0130] According to some optional embodiments of the present invention, the quality control product includes a buffer solution of carboxylated osteocalcin with a determined concentration.

[0131] Use in the preparation of carboxylated osteocalcin detection products

[0132] In the eleventh aspect of the present invention, the present invention proposes use of the kit described in the tenth aspect of the present invention in preparing a carboxylated osteocalcin detection product.

[0133] Method for detecting carboxylated osteocalcin

[0134] In the twelfth aspect of the present invention, the present invention proposes a method for detecting carboxylated osteocalcin. According to an embodiment of the present invention, the method comprises: using the antibody or antigen binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, or the kit described in the tenth aspect of the present invention to detect and process the sample to be tested. The method according to the embodiment of the present invention can be used for high-sensitivity detection of carboxylated osteocalcin, and has strong specificity and simple operation. In practical clinical applications, large quantities of samples can be quickly and high-throughput detected with the help of a chemiluminometer.

[0135] According to an embodiment of the present invention, the detection process is performed in the following manner: the sample to be detected is subjected to a first contact process with an antibody-magnetic particle conjugate to obtain an immune complex; based on the signal of the immune complex, determining whether the sample to be detected contains carboxylated osteocalcin, or determining the content of the carboxylated osteocalcin in the sample to be detected; wherein the antibody in the antibody-magnetic particle conjugate is the antibody or antigen-binding fragment thereof described in the first aspect of the present invention.

[0136] According to an embodiment of the present invention, the detection process further includes: subjecting the sample to be detected to a first contact treatment with an antibody-magnetic particle conjugate; subjecting the first contact treatment product to a second contact treatment with a second osteocalcin antibody to obtain the immune complex; subjecting the immune complex to a third contact treatment with a luminescent substrate to obtain a signal of the immune complex; based on the signal of the immune complex, determining whether the sample to be detected contains carboxylated osteocalcin, or determining the content of the carboxylated osteocalcin in the sample to be detected; wherein the second osteocalcin antibody is modified with a marker; and the marker is used to catalyze the luminescence of the luminescent substrate.

[0137] The present application adopts the immune sandwich method to detect carboxylated osteocalcin. Therefore, the antibody described in the first aspect of the present invention and the second osteocalcin antibody should avoid being the same to prevent the two antibodies from recognizing the same antigenic epitope, thereby causing detection failure.

[0138] According to an embodiment of the present invention, the antibody that recognizes carboxylated osteocalcin is from any antibody or antigen-binding fragment thereof exemplified in the present application.

[0139] According to an embodiment of the present invention, the second osteocalcin antibody is from a commercial osteocalcin antibody, such as R&D Systems, Inc., catalog number MAB11327.

[0140] According to an embodiment of the present invention, the antibody described in the first aspect of the present invention is selected from antibodies that recognize carboxylated osteocalcin. As mentioned above, the antibody or antigen-binding fragment thereof in any of the above examples is bound to a magnetic microsphere through a functional group to form an immunomagnetic bead. Since the antibody has a high affinity with its corresponding antigen, it can be bound to the antigen and fixed to the magnetic microsphere for detection.

[0141] According to an embodiment of the present invention, the magnetic microspheres are selected from composite microspheres formed by ferric oxide or ferroferric oxide magnetic nanoparticles and organic polymer materials. Because they have superparamagnetism, high specific surface area, modifiable functional groups and other characteristics, the inventors choose to immobilize antibodies or antigen-binding fragments thereof on their surfaces.

[0142] According to an embodiment of the present invention, the surface of the composite microsphere is modified to carry one or more active groups, and the active groups can be cross-linked with the amino group or carboxyl group of the carboxylated osteocalcin antibody through amide bonds to form magnetic microspheres coated with the carboxylated osteocalcin antibody.

[0143] According to an embodiment of the present invention, carboxylated osteocalcin antibody (or osteocalcin antibody) can also be directly or indirectly coupled to the surface of magnetic beads through its own amino or carboxyl groups, such as being coated on magnetic microspheres by the method of magnetic beads-streptavidin coupling-biotin-biotin carrier protein indirect coating, or it can be connected to magnetic particles in the reaction in the form of an antibody solution.

[0144] According to an embodiment of the present invention, the second osteocalcin antibody is selected from antibodies that recognize osteocalcin. As mentioned above, the second osteocalcin antibody refers to a commercial osteocalcin antibody modified by an immunolabeling technique (such as enzyme labeling, ferritin labeling, or colloidal gold labeling). According to an embodiment of the present invention, the second osteocalcin antibody is obtained by enzyme labeling.

[0145] According to an embodiment of the present invention, the marker and the second osteocalcin antibody are coupled via an amide bond to form a marker-second osteocalcin antibody conjugate.

[0146] According to an embodiment of the present invention, the coupling method of the marker and the osteocalcin antibody can be obtained based on any method known in the art. For example, 2-Iminothiolane hydrochloride (2-IT), a commonly used activator in the art, is added to the osteocalcin antibody, and Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), a commonly used activator in the art, is added to the marker. The mixing ratio of the activated marker and the osteocalcin antibody is preferably 1:0.5-2, and can be optionally 1:0.5; 1:1; 1:1.5 or 1:2.

[0147] As mentioned above, the immunolabeling technique is to label some substances that are both easy to measure and highly sensitive onto specific antigens or antibody molecules, and to display the properties and content of the antigens or antibodies in the reaction system through the enhanced amplification effect of these markers. According to an embodiment of the present invention, the second osteocalcin antibody is mainly used for the localization analysis of antigens. In some cases, it can also be used to quantitatively detect antigens in samples mixed with a large number of other molecules. Since antibodies have a high affinity with their corresponding antigens, antibodies with easily identifiable markers can locate and analyze antigens, and are an ideal, rapid and inexpensive quantitative determination method.

[0148] According to an embodiment of the present invention, after the second contact treatment and before the third contact treatment, the immune complex is further subjected to a magnetic separation treatment.

[0149] According to an embodiment of the present invention, the antibody-magnetic particle conjugate is obtained by: coupling the magnetic microspheres at a predetermined mass ratio with the antibody or antigen-binding fragment thereof described in the first aspect of the present invention in a MES buffer system to obtain the antibody-magnetic particle conjugate.

[0150] According to an embodiment of the present invention, the mass ratio of the antibody or antigen-binding fragment thereof described in the first aspect of the present invention to the magnetic microspheres is 1 to 20:1000.

[0151] According to an embodiment of the present invention, the coupling reaction time is selected from 5 to 8 hours, preferably 6.5 hours.

[0152] According to an embodiment of the present invention, the coupling reaction temperature is selected from 4 to 8°C, preferably 4°C.

[0153] Illustratively, the antibody or antigen-binding fragment thereof in any of the above examples is coupled to magnetic microspheres to prepare an antibody-magnetic particle conjugate, the second osteocalcin antibody is labeled with alkaline phosphatase (ALP) to prepare a marker-second osteocalcin antibody conjugate, and a 9,10-dihydroacridine derivative at a concentration of 0.005%-0.05% or an adamantane derivative at a concentration of 0.005%-0.05% is used as a luminescent substrate solution. When the reaction occurs, the luminescent substrate is catalytically cleaved under the action of alkaline phosphatase (ALP) to form an unstable excited intermediate. When the excited intermediate returns to the ground state, it emits photons to form a luminescent reaction, and the luminescence intensity of the reaction can be detected using a luminometer.

[0154] According to an embodiment of the present invention, the detection process further includes: taking the calibrator as the sample to be tested, drawing a carboxylated osteocalcin concentration-luminescence value standard curve to obtain the carboxylated osteocalcin content in the unknown sample to be tested; wherein the calibrator contains carboxylated osteocalcin with different concentration gradients.

[0155] According to an embodiment of the present invention, the carboxylated osteocalcin concentration-luminescence value standard curve is obtained by the following method, including:

[0156] (1) Immune reaction: 50 μL of calibrators or quality control products of different concentrations, 50 μL of antibody-magnetic particle conjugate, and 50 μL of marker-second osteocalcin antibody conjugate were added to the reaction tubes in sequence, and mixed and incubated at 37°C for 10 min;

[0157] (2) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μL of a cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0158] (3) Reading: Add 200 μL of luminescent substrate solution, and use the fully automatic chemiluminescence immunoassay analyzer SMART 500H to measure the relative luminescence intensity after alkaline phosphatase catalyzes the substrate to emit light;

[0159] (4) A four-parameter equation was used to fit the detected values ​​to obtain a standard curve of carboxylated osteocalcin concentration-luminescence value.

[0160] For ease of understanding, the above detection method is described in detail by taking the carboxylated osteocalcin chemiluminescence immunoassay method as an example.

[0161] Step 1: coating the carboxylated osteocalcin antibody of any of the above embodiments on the surface of magnetic microparticles to prepare a carboxylated osteocalcin antibody magnetic microsphere buffer solution;

[0162] Step 2: preparing a second osteocalcin antibody solution labeled with a marker;

[0163] Step 3: Mix the sample to be tested, the solution in step 1, and the solution in step 2 in proportion and perform an immune reaction;

[0164] Step 4: After the reaction is complete, the magnetic microparticles are collected by a magnetic field, and a substrate that makes the marker in step 2 emit light is added to obtain a carboxylated osteocalcin concentration-luminescence value standard curve;

[0165] Step 5: Calculate the carboxylated osteocalcin content according to the standard curve.

[0166] The above detection kit and detection method have the following beneficial effects:

[0167] The present application adopts a sandwich reaction mode, and utilizes the principle of combining chemiluminescence detection technology with magnetic microsphere immunoseparation technology to quantitatively detect the content of carboxylated osteocalcin in human serum or plasma samples, thereby ensuring the sensitivity of the detection. Since the experiment adopts the sandwich method, it is pollution-free, highly specific, simple to operate, and has low requirements for sample pretreatment, and can rapidly and high-throughput detect large quantities of samples, which is convenient for clinical reagent application. The present application provides a more accurate, convenient and quick method for clinical detection of carboxylated osteocalcin in samples.

[0168] Use in the preparation of medicines

[0169] The thirteenth aspect of the present invention is the use of the antibody or antigen-binding fragment described in the first aspect of the present invention, the recombinant protein described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the recombinant cell described in the fifth aspect of the present invention, the conjugate described in the sixth aspect of the present invention, and the composition described in the eighth aspect of the present invention in the preparation of a medicament, wherein the medicament is used to prevent and / or treat bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity, and bone tumors.

[0170] method

[0171] In the fourteenth aspect of the present invention, the present invention proposes a method for treating or preventing bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity, and bone tumors. According to an embodiment of the present invention. The method comprises: administering a pharmaceutically acceptable amount of the aforementioned antibody or antigen-binding fragment, the aforementioned recombinant protein, the aforementioned composition, or the aforementioned conjugate to a subject. The method of the present invention can effectively treat or prevent bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity, and bone tumors.

[0172] The effective amount of the antibody or antigen-binding fragment, recombinant protein, composition or conjugate of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, or the dose may be reduced proportionally.

[0173] The antibodies or antigen binding fragments, recombinant proteins, compositions or conjugates of the present invention can be incorporated into drugs suitable for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). These drugs can be prepared in various forms. For example, liquid, semisolid and solid dosage forms, including but not limited to liquid solutions (e.g., injection solutions and infusion solutions) or lyophilized powders. Typical drugs are in the form of injection solutions or infusion solutions. The aforementioned antibodies or antigen binding fragments, recombinant proteins, compositions or conjugates can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.

[0174] According to an embodiment of the present invention, the administration route of the method is subcutaneous injection or intravenous injection.

[0175] The sequence table of the present invention is as follows:

[0176] Sequence Listing

[0177]

[0178]

[0179] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0180] Example

[0181] Example 1: Synthesis of carboxylated osteocalcin peptides, non-carboxylated osteocalcin peptides and full-length osteocalcin antigen

[0182] Shanghai Botai Biotechnology Co., Ltd. was used to synthesize the full-length osteocalcin antigen (the specific amino acid sequence is shown in SEQ ID NO: 15), the non-carboxylated osteocalcin peptide OC-BSA (the specific amino acid sequence is shown in SEQ ID NO: 16), the carboxylated osteocalcin peptide cOC-KLH (the specific amino acid sequence is shown in SEQ ID NO: 17), and the carboxylated osteocalcin peptide cOC-BSA (the specific amino acid sequence is shown in SEQ ID NO: 18).

[0183] Example 2: Immunization of BALB / c mice with carboxylated osteocalcin protein

[0184] In this example, the carboxylated osteocalcin protein synthesized in Example 1 was used to immunize BALB / c mice, and the antibody serum titer of the mice was detected. The specific steps are as follows:

[0185] BALB / c mice aged 6 to 8 weeks were selected for the following immunization procedure: for the first immunization, 25 μg of carboxylated osteocalcin was mixed with an equal amount of Freund's complete adjuvant and injected subcutaneously at multiple points after emulsification; 14 days after the first immunization, 12.5 μg of carboxylated osteocalcin was mixed with Freund's incomplete adjuvant and emulsified for booster immunization. 14 days after the second immunization, 12.5 μg of carboxylated osteocalcin was mixed with Freund's incomplete adjuvant and emulsified for booster immunization. 14 days after the third immunization, blood was collected and serum was separated. ELISA plates were coated with 1 μg / mL carboxylated osteocalcin, and indirect ELISA tests were performed to determine the serum titer. The results showed that the titer of the prepared mouse antiserum was 1:72900. The typical test results of immunized mouse serum are shown in Table 2.

[0186] Table 2

[0187] Serum dilution multiple OD450 100 2.932 300 2.524 900 1.933 2700 1.463 8100 0.752 24300 0.593 72900 0.372 Background 0.096

[0188] Example 3: Cell fusion

[0189] In Example 2, cell fusion was performed 3 days after the booster immunization of mice. After removing the eyeballs of the mice to collect blood, the mice were killed by dislocation, placed in a 70% alcohol bottle for 2 minutes, and then fixed on a foam board in a biosafety cabinet. The abdominal skin was untied to find the spleen, which was removed with forceps and gently ground into a 200-mesh stainless steel filter. The cells were gently rinsed with DMEM culture medium (Thermo, 11965092), and then centrifuged at 200g for 10 minutes at room temperature. The supernatant was discarded and set aside. When preparing feeder cells, the mice were killed by dislocation, placed in a 70% alcohol bottle for 2 minutes, and then fixed on a foam board in a biosafety cabinet. The abdominal skin was untied, and PBS was drawn with a syringe and gently injected into the peritoneum. The liquid containing the feeder cells was washed out from the other side, and then centrifuged at 200g for 10 minutes at room temperature. The supernatant was discarded and set aside. 2.0×10 7 FO myeloma cells and 2.0×10 8 The spleen cells were mixed, centrifuged at 200g for 10 minutes, the supernatant was discarded, and the mixture was gently shaken to mix. In a 37°C water bath, 1 mL of a 50% PEG-1450 (Merk, P1458) aqueous solution was added dropwise within 90 seconds, followed by 20 mL of DMEM culture medium. The mixture was centrifuged at 200g for 10 minutes, the supernatant was discarded, and the mixture was washed repeatedly. The mixture was centrifuged at 200g for 10 minutes, the supernatant was discarded, and hybridoma cells were obtained. The cells were plated into 10 96-well culture plates with 150 μL per well. 10,000 cells / well of feeder layer cells were added to the above 10 96-well cell culture plates, 100 μL per well, and the culture plates were marked and placed in a cell culture incubator at 37°C containing 5% CO2 for culture. On the second day, HAT screening medium (Merk, H0262) was added, and then HAT selection culture was used for 1-2 days. A large number of tumor cells died, and after 3-4 days, the tumor cells disappeared, and hybrid cells formed small colonies. After 7-10 days of HAT screening culture medium, HT culture medium (Merk, H0137) should be used, and then maintained for another 2 weeks, and then 20% FBS (ExCell, FSP500) DMEM culture medium was used for continued culture. During the above selection culture period, when the hybridoma cells covered 1 / 10 of the bottom area of ​​the well, specific antibodies could be detected to screen out the desired hybridoma cell lines. During the selection culture period, half of the culture medium was generally replaced every 2-3 days.

[0190] Example 4: Screening and subcloning of positive hybridoma cell lines

[0191] First, the optimal coating amount of carboxylated osteocalcin as an antigen was determined by orthogonal experiments. 0.5, 1.0, 2.0, and 4.0 μg of carboxylated osteocalcin were coated on a 96-well plate, and 6 wells of each concentration were set as 3 positive and 3 negative. Founder titration was performed with positive serum from mice immunized with carboxylated osteocalcin at different dilutions, and negative serum from unimmunized mice was used as a negative control. 96-well ELISA plates were coated with 0.5 μg of purified carboxylated osteocalcin per well and incubated at 4°C overnight; washed twice with PBST; 200 μL of 1% BSA in PBS was added to each well, blocked at room temperature for 2 hours, and then placed on trifold paper and patted dry; sample addition: 0.1 mL of the sample to be tested was added to the reaction well, incubated at 37°C for 1 hour, and then washed, and blank wells (no sample added), negative control wells, and positive control wells were made at the same time. 0.1 mL of newly diluted antibody was added to each reaction well, incubated at 37°C for 1 hour, and then washed 3 times. Add enzyme-labeled secondary antibody: Add 0.1 mL of freshly diluted enzyme-labeled antibody to each reaction well. Incubate at 37°C for 1 hour and wash 3 times. Add substrate solution for color development: Add 0.1 mL of TMB substrate solution to each reaction well and let stand at room temperature for 10 minutes. Add 0.1 mL of 1M H2SO4 to each reaction well. Measure the OD value to determine the result, and use an enzyme-labeled instrument to measure the absorbance value (A450) at 450 nm. A value that is 2.1 times or more of the negative control OD value is considered positive (calculated after adjusting the blank control well to zero). Select the hybridoma cell monoclonal clone that resists carboxylated osteocalcin.

[0192] According to the above method, the positive hybridoma cells screened were subcloned, and the original wells were diluted with HAT selection medium by limiting dilution method and redistributed into 96-well culture plates, and then the morphology and number of cells were observed. The cells were adjusted to 3-10 cells / mL. Take the cell culture plate with feeder cell layer prepared the day before, and add 100 μL of diluted cells to each well. Culture statically in a 37°C, 5% CO2 incubator. Change the medium on the 7th day, and change the medium once every 2-3 days thereafter. Cell clones can be seen on the 8th to 9th day, and the antibody activity is detected in time. The cells in the positive wells are transferred to a 24-well plate for expansion and culture. Each clone should be frozen as soon as possible, and finally the hybridoma cell line with clone number W027 is selected for antibody production.

[0193] Example 5: Mass preparation of monoclonal antibodies and determination of antibody titer

[0194] (1) Large-scale preparation of monoclonal antibodies

[0195] 8-week-old BALB / C mice were intraperitoneally injected with 0.5 mL of Freund's incomplete adjuvant. Two weeks later, 1 × 10 6Hybridoma cells can produce ascites 7 to 10 days after inoculation. Closely observe the health status and ascites signs of the animals. When ascites is as much as possible and before the mice die, kill the mice and use a dropper to suck the ascites into a test tube. 5 to 10 mL of ascites can be obtained from one mouse. Ascites can also be extracted with a syringe and can be collected repeatedly several times. Centrifuge the ascites at 3000g for 10 minutes, discard the upper layer of fat and the bottom precipitate, collect the supernatant and pack it at -20℃. After the ascites supernatant is thawed and equilibrated to room temperature, add 1 / 10 volume of 1M Tris-HCl pH8.0 to adjust the sample pH to 8.0. The protein G affinity column was balanced with 20 column volumes of 100mM Tris-HCl at pH 8.0, and the ascites supernatant after adjusting the pH to 8.0 was loaded onto the column, followed by washing with 20 column volumes of 100mM Tris-HCl at pH 8.0, and finally eluting the antibody with 100mM Glycine-HCL pH 2.5. The antibody eluate was added to a concentrator tube (Millipore, UFC801008, 10K) and centrifuged at room temperature for 20 minutes at 3000×g in a centrifuge (Xiangyi, L550). The solution was centrifuged in batches until the volume of the solution reached 1mL / concentrator tube (2 tubes), 4mL of 10mM PBS pH 7.4 buffer was added, and centrifugation at room temperature for 20 minutes at 3000×g was continued. The centrifugation was repeated 3 times to make the antibody buffer 10mM PBS pH 7.4, and 10mM PBS pH 7.4 was added to a total volume of 10mL. Finally, 2 mL / tube of the concentrated antibody solution was dispensed into centrifuge tubes and stored at -80° C. The antibody concentration was determined using a BCA kit (Solabo, PC0020), and the concentration of the purified monoclonal antibody was 2.4 mg / mL.

[0196] (2) Antibody titer determination

[0197] The titer of carboxylated osteocalcin antibody W027 was detected by ELISA indirect method. Carboxylated osteocalcin was diluted with PBS and coated in a 96-well ELISA plate at 0.2 μg / mL and 100 μL / well. After overnight at 4°C, the ELISA plate was washed twice with PBST solution, 300 μL / well each time, and patted dry after washing. The ELISA plate was blocked with 1% BSA PBS solution, 200 μL / well, at room temperature for 2 hours, and patted dry after blocking; carboxylated osteocalcin antibody W027 diluted to 20 ng / mL with PTB was added, reacted in a 37°C incubator for 1 hour, and the ELISA plate was washed twice with PBST solution, 300 μL / well each time. Patted dry after washing. HRP-labeled goat anti-mouse antibody diluted 5000 times with PTB was added, reacted in a 37°C incubator for 1 hour, and the ELISA plate was washed twice with PBST solution, 300 μL / well each time. Patted dry after washing. TMB substrate solution was added, 100 μL / well was reacted at room temperature for 10 minutes, and 100 μL / well of 1M H2SO4 was added to terminate the reaction. The absorbance value (A450) was measured at 450 nm using an ELISA reader. The results are shown in Table 3, and it can be seen that the titer of the purified antibody is 1:729000.

[0198] Table 3

[0199] Antibody dilution factor OD450 1000 2.109 3000 1.593 9000 1.362 27000 1.091 81000 0.876 243000 0.621 729000 0.374 Background 0.052

[0200] Example 6: Sequence analysis of monoclonal antibodies

[0201] (1) Monoclonal antibody subtype identification

[0202] Hybridoma cell line W027 was cultured in a 10 cm diameter cell culture dish (37°C, 5% CO2) using DMEM medium (GIBCO, #C11995500BT) supplemented with 10% serum. After 7 days of culture, the cells were transferred to a 15 mL centrifuge tube and 4 × 10 6 After centrifugation at 200 g for 5 minutes, the supernatant was discarded, and the centrifuge tube was inverted to drain the liquid in the tube. The cells in the tube were synthesized into cDNA using the reverse transcription kit (Qiagen, 74134) of QIAGEN Company.

[0203] The antibody subtype is determined by PCR using antibody subtype-specific primers. The above-synthesized cDNA is used as a PCR reaction template. PCR reaction solution system: TAKARA Ex Taq (5U / μL, TAKARA, RR001B), 0.25μL; 10×Ex Taq Buffer, 5μL; dNTP mixture (2.5mM each), 4μL; template cDNA, 1μL; upstream primer (100μM), 1μL; downstream primer (100μM), 1μL; add double distilled water to a total volume of 50μL. PCR reaction temperature program: 94°C for 5 minutes for pre-denaturation, temperature cycle 30 times (94°C for 1 minute, 57°C for 1 minute, 72°C for 1 minute), and 72°C for 10 minutes for extension. After the reaction, 10μL of each PCR product was loaded on a 1% agarose gel for electrophoresis. The electrophoresis pattern is shown as follows. Figure 1 The order of samples added to each lane is shown in Table 5. The subtype of the antibody can be inferred from the PCR product results (Table 4). The monoclonal antibody W027 obtained in the present invention has a heavy chain of IgG1 and a light chain of kappa.

[0204] Table 4

[0205]

[0206] Where S=C or G, M=A or C, R=A or G, and W=A or T

[0207] Table 5

[0208]

[0209]

[0210] (2) Sequencing of the variable region (V region) of the hybridoma cell line W027

[0211] The fragment obtained after PCR amplification of the V region of the antibody of cell line W027 (see above) was cut from the agarose gel and extracted with a DNA extraction kit (Qiagen, 74134). The extracted DNA fragment was linked to the pEASY-T1 cloning vector and transformed into Trans1-T1 competent cells (Transgen, CT101-1). The transformed bacterial colonies were picked into LB culture medium and DNA sequencing was performed after overnight culture. The light chain V region nucleic acid sequence of the antibody (W027) for recognizing the carboxylation site of osteocalcin provided by the present invention is shown in SEQ ID NO:9, and the nucleic acid sequence of the heavy chain V region is shown in SEQ ID NO:10.

[0212] Example 7: Identification of the specificity of antibody W027 in detecting carboxylated osteocalcin

[0213] The specific ability of antibody W027 to detect free carboxylated osteocalcin was evaluated by ELISA. In this experiment, carboxylated osteocalcin peptides and uncarboxylated osteocalcin were diluted in PBS as antigens and coated in 96-well ELISA plates at a coating concentration of 1 μg / mL and 0.5 ug / mL in a volume of 100 μL / well. After overnight coating at 4°C, the ELISA plates were washed twice with PBST solution, 300 μL / well each time. After washing, the plates were patted dry and blocked with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. After patting dry, antibody W027 (diluted to 10 ng / mL with PTB) was added to the blocked ELISA plates, 100 μL / well, and reacted in a 37°C incubator for 1 hour. After patting dry, the plates were washed 3 times with PBST, 300 μL / well each time. Pat dry, add HRP-labeled goat anti-mouse antibody diluted 5000 times with PTB to the ELISA plate, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well. Pat dry, add TMB substrate solution to the ELISA plate, 100 μL / well, at room temperature for 10 minutes, then add 100 μL / well of 1M H2SO4 to terminate the reaction. Use an ELISA reader to measure the absorbance (A450) at 450nm. The experimental results are shown in Table 6, indicating that antibody W027 has good specificity for detecting carboxylated osteocalcin.

[0214] Table 6

[0215] Antigen concentration (ng / mL) Uncarboxylated osteocalcin peptide Carboxylated osteocalcin peptide 1000 0.023 1.632 500 0.015 0.965 Background 0.019 0.021

[0216] Example 8: Application of the ELISA kit prepared using antibody W027 in detecting carboxylated osteocalcin in human serum

[0217] (1) Horseradish peroxidase (HRP) labeling of antibody W027 and identification of the labeled product

[0218] 0.5 mL of antibody W027 (20 nmol, 3 mg) was added to a dialysis bag (10 KDa, 1 cm width) and dialyzed in 2 L of 10 mM PBS solution (pH 7.4) at 4 ° C overnight. The next day, the dialysis bag containing the antibody solution was placed in 1 L of 10 mM carbonate buffer (pH 9.5) and dialyzed for 2 hours at room temperature to prepare for coupling with activated HRP.

[0219] At the same time, use an analytical balance to accurately weigh 1 mg of HRP, add 0.2 mL of ultrapure water to dissolve it, and make the HRP concentration 5 mg / mL. Add 40 μL of 0.1M NaIO4 to the above HRP solution, place it on a horizontal shaker, and react (activate) at room temperature in the dark for 20 minutes. Add the activated HRP solution to a dialysis bag (10KDa, width 1 cm) and dialyze it in 2L 1mM sodium acetate buffer (pH 4.4) at 4°C overnight. Carefully aspirate the dialyzed HRP solution and transfer it to a new 1.5 mL centrifuge tube, add 1 / 10 volume of 0.2M carbonate buffer, and raise the pH of the activated HRP solution to 9.0-9.5.

[0220] Mix the above antibodies and HRP (for coupling reaction), place on a horizontal shaker, and react at room temperature in the dark for 4 hours. After the coupling reaction is completed, add 10 μL (pre-cooled ultrapure water) freshly prepared NaBH4, and terminate the reaction at 4°C in the dark overnight. Move the antibody solution after the coupling reaction is terminated to a dialysis bag (10KDa, width 1cm), stir and dialyze at room temperature for 2 hours. Finally, transfer the solution to a brown centrifuge tube and store at 4°C.

[0221] (2) Detection of carboxylated osteocalcin in human serum using an ELISA kit prepared using antibody W027

[0222] In this experiment, osteocalcin antibody (SCBT, sc-74495) was diluted to 1 μg / mL with PBS, and then 100 μL / well was coated in a 96-well ELISA plate (overnight at 4°C). The plate was washed twice with 300 μL / well PBST. Pat dry, block the ELISA plate with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. Pat dry, add 1000-fold diluted HRP-labeled antibody W027 (diluted with PTB) solution 25 μL / well to the ELISA plate, and then add different concentrations of human serum samples (serum of patients with clinically confirmed bone-related diseases was selected as the sample to be tested, and normal human serum was used as the negative sample), 75 μL / well, and reacted in a 37°C incubator for 45 minutes. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add TMB substrate solution, 100 μL / well, and react at room temperature for 10 minutes. Then, 100 μL / well of 1M H2SO4 was added to terminate the reaction, and the absorbance (A450) was measured at 450 nm using an ELISA reader. The results are shown in Table 7, indicating that the ELISA kit prepared using the antibody W027 of the present invention can efficiently detect carboxylated osteocalcin in human serum.

[0223] Table 7

[0224] Patient serum samples <![CDATA[OD 450 ]]> <![CDATA[OD 450(空白) ]]> Patient 1 0.659 0.076 Patient 2 0.935 0.034 Patient 3 0.793 0.078 Patient 4 0.934 0.048 Patient 5 0.486 0.056

[0225] Example 9: Detection of carboxylated osteocalcin based on chemiluminescence

[0226] This example uses the carboxylated osteocalcin antibody prepared in the previous example to design a detection kit. The magnetic microsphere separation chemiluminescence immunoassay method is used as an example. The detection principle is as follows: Figure 2 As shown, the specific steps of the kit for detecting the content of carboxylated osteocalcin in the sample to be tested are demonstrated.

[0227] Instrument: The company's self-developed chemiluminescence detector;

[0228] Reagents: labeled alkaline phosphatase (ALP) was purchased from BBI, UK, model: ALPI12G; SMCC was purchased from thermofisher scientific, item number: 22360; 2-IT was purchased from thermo fisher scientific, CAS: 4781-83-3; item number: 26101; carboxyl-modified microparticles were purchased from thermo fisher scientific; EDC was purchased from SIMGA, CAS: 25952-53-8, item number: E7750; the antibodies were the G069 antibody prepared in the above example and the commercial osteocalcin antibody, purchased from R&D Systems, Inc., item number MAB11327; the luminescent substrate came from the company's self-developed reagents; the remaining reagents were conventional products purchased from the market.

[0229] Experiment 1: Magnetic microspheres labeled with carboxylated osteocalcin antibody

[0230] Take 20 mg of carboxyl-modified microparticle solution, and let the magnetic microspheres with superparamagnetism, uniform particle size, and carboxyl (COOH-) active groups on the surface settle under the action of a magnetic field (magnetic separation) for 10 minutes, remove the supernatant, and wash the settled magnetic microspheres with an activation buffer with a molar concentration of 0.05 M (2-(N-morpholine)ethanesulfonic acid) MES, pH 6.0 buffer for 3 times, each time using 2 mL.

[0231] The washed magnetic microspheres were fully suspended with 1.0 mL of activation buffer (2-(N-morpholinoline)ethanesulfonic acid) MES, pH 6.0, and then the activator 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) was added and the suspension was reacted at room temperature for 30 minutes. The reaction molar concentration of EDC was 7.5 mM.

[0232] Take 1.0 mg of carboxylated osteocalcin antibody and concentrate it to 2.5 mg / mL.

[0233] The carboxylated osteocalcin antibody concentrated to 2.5 mg / mL was added to 20 mg of the activated magnetic microsphere solution according to 1.0 mg of the carboxylated osteocalcin-coupled carrier protein antigen, and the mixture was gently shaken to mix well. The mixture was reacted at 4° C. under suspension conditions for 6.5 hours, so that the carboxylated osteocalcin antibody was covalently coupled to the surface of the magnetic microspheres. The mixture was named reagent A.

[0234] Experiment 2: Alkaline phosphatase labeled secondary osteocalcin antibody

[0235] 1.0 mg of the second osteocalcin antibody was concentrated to 2.5 mg / mL, and 5 μL of activator 2-Iminothiolane hydrochloride (2-IT) solution with a concentration of 13.76 mg / mL was added, and the mixture was reacted at room temperature for 15 minutes. The activated antibody was collected after desalting using a Sephadex G25 gel column.

[0236] 1.2 mg of alkaline phosphatase was concentrated to 2.5 mg / mL, and 12 μL of activator Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) solution with a concentration of 6.69 mg / mL was added, and the mixture was reacted at room temperature for 15 minutes. The activated alkaline phosphatase was collected after desalting using a Sephadex G25 gel column.

[0237] The activated second osteocalcin antibody and alkaline phosphatase were mixed at a ratio of 1.0 mg of the second osteocalcin antibody to 1.0 mg of alkaline phosphatase, and the mixture was allowed to react at 4° C. for 18 hours.

[0238] The unconnected second osteocalcin antibody and alkaline phosphatase were removed by separation and purification using a Supperdex200 gel chromatography column, and the connection product was stored at 4°C and named as reagent B.

[0239] Experiment 3: Chemiluminescent immunoassay for separation of carboxylated osteocalcin using magnetic microspheres

[0240] (1) Immunoreaction: Take 50 μL of the calibrator or quality control and add 50 μL of reagent A prepared in Experiment 1 and 50 μL of reagent B prepared in Experiment 2 into the reaction tubes, mix and incubate at 37°C for 10 min.

[0241] (2) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μL of a cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0242] (3) Reading: Add 200 μL of luminescent substrate solution, and use a self-developed chemiluminescence detector to measure the relative luminescence intensity (RLU) after alkaline phosphatase catalyzes the substrate to emit light;

[0243] (4) A four-parameter equation was used to fit the detected values ​​to obtain a standard curve of carboxylated osteocalcin concentration-luminescence value.

[0244] (5) 50 μL of the sample to be tested, 50 μL of reagent A prepared in Experiment 1, and 50 μL of reagent B prepared in Experiment 2 were added to the reaction tube in sequence, mixed and incubated at 37°C for 15 min;

[0245] (6) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μL of a cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0246] (7) Reading: Add 200 μL of luminescent substrate solution, and use a self-developed chemiluminescence detector to measure the relative luminescence intensity (RLU) after ALP catalyzes the substrate to emit light;

[0247] (8) The luminescence intensity of the sample to be tested is compared with the standard curve of step (4), and the content of carboxylated osteocalcin in the sample to be tested can be calculated using a four-parameter equation fitting.

[0248] In summary, the monoclonal antibody of carboxylated osteocalcin prepared in this application has the characteristics of high affinity and specificity. The carboxylated osteocalcin detection kit prepared based on the antibody can be used for rapid detection of the carboxylated osteocalcin content in serum or plasma samples, with high sensitivity, strong specificity, simple operation and low pre-treatment requirements for samples. By being used in conjunction with a fully automatic chemiluminescence analyzer, the operating steps are greatly simplified, the detection speed and detection flux are increased, the detection efficiency is improved, and the errors caused by human operation are avoided.

[0249] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0250] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. An antibody or an antigen-binding fragment thereof, characterized in that: include: The light chain variable region CDR1, CDR2, and CDR3 sequences are shown in the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively; and, The heavy chain variable region CDR1, CDR2, and CDR3 sequences are shown in the amino acid sequences of SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, respectively; Wherein, the antibody or antigen-binding fragment thereof targets carboxylated osteocalcin.

2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: include: The light chain variable region is shown in the amino acid sequence of SEQ ID NO:1, and the heavy chain variable region is shown in the amino acid sequence of SEQ ID NO:

2.

3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that: It further comprises at least one of a heavy chain constant region and a light chain constant region, wherein at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from a mammalian antibody.

4. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The heavy chain constant region and the light chain constant region are derived from at least one of mouse antibody, human antibody, bovine antibody, horse antibody, porcine antibody, sheep antibody, goat antibody, dog antibody, cat antibody, rabbit antibody, donkey antibody, deer antibody, mink antibody or their mutants.

5. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The heavy chain constant region comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; or The light chain constant region comprises a light chain constant region selected from a kappa-type or a lambda-type.

6. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The heavy chain constant region and the light chain constant region are both derived from murine antibodies or mutants thereof.

7. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The N-terminus of the heavy chain constant region is connected to the C-terminus of the heavy chain variable region; and / or The N-terminus of the light chain constant region is connected to the C-terminus of the light chain variable region.

8. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO: 11; and / or The light chain constant region comprises the amino acid sequence shown in SEQ ID NO:

12.

9. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: The antibody or antigen-binding fragment comprises: The heavy chain of the amino acid sequence is shown in SEQ ID NO: 13; and / or The light chain has an amino acid sequence as shown in SEQ ID NO:

14.

10. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody comprises at least one selected from polyclonal antibodies and full-length monoclonal antibodies; The antigen-binding fragment comprises at least one selected from the group consisting of Fab antibody, Fab' antibody, F(ab')2 antibody, Fv antibody, and single-chain antibody.

11. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

12. The nucleic acid molecule according to claim 11, characterized in that The nucleic acid molecule comprises: Having the nucleic acid sequence encoding the light chain variable region as shown in SEQ ID NO:9; or The nucleic acid sequence encoding the heavy chain variable region is shown in SEQ ID NO:

10.

13. An expression vector, characterized in that: Carrying the nucleic acid molecule according to claim 11 or 12.

14. A recombinant cell, characterized in that Include: Carrying the nucleic acid molecule of claim 11 or 12, or the expression vector of claim 13; or Expressing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

15. A method for preparing an antibody or antigen fragment that recognizes the carboxylation site of osteocalcin, characterized in that: include: Cultivate the recombinant cell of claim 14.

16. A composition, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, the nucleic acid molecule according to claim 11 or 12, the expression vector according to claim 13, or the recombinant cell according to claim 14.

17. Use of the antibody or antigen-binding fragment of any one of claims 1 to 10, the nucleic acid molecule of claim 11 or 12, the expression vector of claim 13, the recombinant cell of claim 14, or the composition of claim 16 in preparing a kit, characterized in that: The kit is used for detecting carboxylated osteocalcin.

18. A kit, characterized in that: include: At least one of the antibody or antigen-binding fragment of any one of claims 1 to 10, the nucleic acid molecule of claim 11 or 12, the expression vector of claim 13, the recombinant cell of claim 14, and the composition of claim 16.

19. The kit according to claim 18, characterized in that The kit comprises the antibody or antigen-binding fragment according to any one of claims 1 to 10, magnetic particles, a second osteocalcin antibody, and a luminescent substrate; wherein the magnetic particles are coupled to the antibody or antigen-binding fragment; The second osteocalcin antibody has a marker modification; The label is used to catalyze the luminescent substrate to emit light.

20. The kit according to claim 19, characterized in that: The particle size of the magnetic particles is no greater than 10 μm.

21. The kit according to claim 19, characterized in that The particle size of the magnetic particles is 0.5-10 μm.

22. The kit according to claim 19, characterized in that The marker includes at least one of a biological enzyme and fluorescein.

23. The kit according to claim 22, characterized in that The biological enzyme includes at least one of horseradish peroxidase and alkaline phosphatase.

24. The kit according to claim 19, characterized in that The second osteocalcin antibody specifically recognizes the conserved region of osteocalcin.

25. The kit according to claim 19, characterized in that The luminescent substrate is selected from at least one of o-phenylenediamine, luminol and acridinium ester.

26. The kit according to claim 19, characterized in that The luminescent substrate is provided in liquid form.

27. The kit according to claim 26, characterized in that The luminescent substrate liquid further includes a buffer solution.

28. The kit according to claim 27, characterized in that The buffer solution includes at least one selected from phosphate buffer, carbonate buffer, Tris buffer and citrate buffer.

29. The kit according to claim 19, characterized in that The kit further comprises a calibrator of carboxylated osteocalcin protein and / or a quality control substance of carboxylated osteocalcin protein.

30. Use of the kit according to any one of claims 18 to 29 in the preparation of a carboxylated osteocalcin detection product.

31. A method for detecting carboxylated osteocalcin in vitro for non-disease diagnosis purposes, characterized in that: include: The sample to be tested is subjected to detection treatment using the antibody or antigen-binding fragment described in any one of claims 1 to 10, or the kit described in any one of claims 18 to 29.

32. The method according to claim 31, characterized in that The detection process is performed in the following manner: the sample to be tested is subjected to a first contact process with an antibody-magnetic particle conjugate to obtain an immune complex; Based on the signal of the immune complex, determining whether the sample to be detected contains carboxylated osteocalcin, or determining the content of the carboxylated osteocalcin in the sample to be detected; Wherein, the antibody in the antibody-magnetic particle conjugate is the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

33. The method according to claim 32, characterized in that The detection process further comprises: performing a first contact treatment on the sample to be tested and the antibody-magnetic particle conjugate; subjecting the first contact treatment product to a second contact treatment with a second osteocalcin antibody to obtain the immune complex; performing a third contact treatment on the immune complex and the luminescent substrate to obtain a signal of the immune complex; Based on the signal of the immune complex, determining whether the sample to be detected contains carboxylated osteocalcin, or determining the content of the carboxylated osteocalcin in the sample to be detected; wherein the second osteocalcin antibody has a marker modification; The label is used to catalyze the luminescent substrate to emit light.

34. The method according to claim 33, characterized in that After the second contact treatment and before the third contact treatment, the immune complex is further subjected to magnetic separation treatment.

35. The method according to claim 32, characterized in that The antibody-magnetic particle conjugate is obtained by the following method: The magnetic microspheres at a predetermined mass ratio are coupled with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10 in a MES buffer system to obtain the antibody-magnetic microparticle conjugate.

36. The method according to claim 35, characterized in that The mass ratio of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10 to the magnetic microspheres is 1 to 20:1000.

37. The method according to claim 35, characterized in that The coupling reaction time is selected from 5 to 8 hours.

38. The method according to claim 35, characterized in that The coupling reaction time is selected from 6.5 hours.

39. The method according to claim 35, characterized in that The coupling reaction temperature is selected from 4 to 8°C.

40. The method according to claim 35, characterized in that The coupling reaction temperature is selected from 4°C.

41. The method according to claim 31, characterized in that The detection process further comprises: Taking the calibrator as the sample to be tested, a carboxylated osteocalcin concentration-luminescence value standard curve is drawn to obtain the carboxylated osteocalcin content in the unknown sample to be tested; wherein the calibrator contains carboxylated osteocalcin with different concentration gradients.

Citation Information

Cited By

  • Chemiluminescence determination kit for osteocalcin

    CN121293348A